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The first structure of a bacterial -phosphoglucomutase with
an overall fold similar to eukaryotic phosphomannomutases
is reported. Unlike most -phosphoglucomutases within the
-d-phosphohexomutase superfamily, it belongs to subclass
IIb of the haloacid dehalogenase superfamily (HADSF). It
catalyzes the reversible conversion of -glucose 1-phosphate
to glucose 6-phosphate. The crystal structure of -phospho-
glucomutase from Lactococcus lactis (APGM) was deter-
mined at 1.5 A˚ resolution and contains a sulfate and a glycerol
bound at the enzyme active site that partially mimic the
substrate. A dimeric form of APGM is present in the crystal
and in solution, an arrangement that may be functionally
relevant. The catalytic mechanism of APGM and its strict
specificity towards -glucose 1-phosphate are discussed.
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1. Introduction
-Phosphoglucomutase (-PGM; EC 5.4.2.2) is present in all
organisms from bacteria to animals and plants (Whitehouse
et al., 1998). This enzyme catalyzes the interconversion of
-glucose 1-phosphate to glucose 6-phosphate and plays
distinct roles in different organisms. In animals and plants,
-PGM is mainly involved in the synthesis and utilization of
storage carbohydrates such as glycogen and starch (Villar-
Palasi & Larner, 1970; Fettke et al., 2009). In bacteria, -PGM
is involved in sugar utilization and also in the synthesis of
UDP-glucose, a sugar donor for the production of glucose-
containing polysaccharides. In the last decade, a large number
of studies have associated the virulence of several pathogenic
bacteria with the presence of -PGM (Plant et al., 2006;
Paterson et al., 2009).
Lactococcus lactis is a lactic acid bacterium that is widely
used in starter cultures for the manufacture of fermented dairy
products such as cheese and buttermilk. Its enormous
economic value has rendered this typical homofermentative
bacterium as one of the most extensively studied members of
the lactic acid bacteria. L. lactis possesses two distinct PGMs
with specificity for - or -anomers of phosphoglucose.
-PGM, a member of haloacid dehalogenase superfamily
(HADSF) class I, catalyzes the reversible conversion of
-glucose 1-phosphate to glucose 6-phosphate and is involved
in the degradation pathways of maltose and trehalose
(Andersson et al., 2001; Levander et al., 2001; Lahiri et al.,
2002). -PGM of L. lactis (APGM) catalyzes the inter-
conversion of -glucose 1-phosphate to glucose 6-phosphate
and is essential in the utilization of galactose via the Leloir
pathway (Grossiord et al., 1998; Neves et al., 2006). APGM has
also been implicated in the synthesis of precursors of cell-wall
polysaccharides and exopolysaccharides (Delcour et al., 1999;
Kleerebezem et al., 1999). Therefore, APGM plays an
important role in the processes of galactose degradation and
the formation of precursors for biosynthetic pathways during
growth on glucose or other carbohydrates.
Most of the bacterial and eukaryotic -PGMs that utilize
-glucose 1-phosphate belong to the -d-phosphohexomutase
superfamily (IPR005841). These are enzymes consisting of
four domains that are usually observed as monomers with a
molecular mass larger than 45 kDa (Shackelford et al., 2004).
A conserved serine is utilized as a catalytic residue that is
phosphorylated during the course of reaction. APGM shares
no sequence or structure similarity with the common -PGMs
of the -d-phosphohexomutase superfamily.
In contrast to the known bacterial -PGMs, the lactococcal
APGM enzyme belongs to the HADSF (Neves et al., 2006).
The HADSF is composed of more than 3000 proteins, which
are mainly involved in phosphoryl-transfer reactions (Allen &
Dunaway-Mariano, 2004). Members of the HADSF are typi-
cally composed of two domains: the core and cap domains. The
core domain contains most of the conserved catalytic residues,
while the cap domain acts as a lid over the core domain and
differentiates according to specific substrates and catalytic
reactions (Lahiri et al., 2004; Allen & Dunaway-Mariano,
2009). An example of a strictly conserved amino-acid residue
is the aspartate that acts as a nucleophile and mediates the
transfer of the phosphoryl group (Asp8 in APGM). Members
of the HADSF also share a catalytic requirement for a metal
cofactor, usually Mg2+. Phylogenetic studies of HADSF
proteins have suggested a common origin for APGM and
the eukaryotic phosphomannomutases (PMMs; IPR005002;
Neves et al., 2006). However, APGM shows strict specificity
for -glucose 1-phosphate, whereas the eukaryotic phospho-
mannomutases generally use both -mannose 1-phosphate
and -glucose 1-phosphate as substrates (Pirard et al., 1999;
Neves et al., 2006). Notably, the sequence identity between
-phosphoglucomutase and -phosphoglucomutase from
L. lactis is only 10% (they belong to distinct clades of the
phylogenetic tree; Neves et al., 2006) and results in significant
structural differences, including different topologies and
positions of the cap domain in the sequence. These observa-
tions suggest that L. lactis APGM is mechanistically closer to
the PMMs than to the -PGMs.
In this work, we report the first crystal structure of APGM.
It was determined by the single-wavelength anomalous
dispersion (SAD) method based on a Pt derivative and was
refined to 1.5 A˚ resolution. The structure is compared with
other members of the HADSF and specific features of the
enzyme with impact on substrate specificity and catalytic
mechanism are discussed.
2. Materials and methods
2.1. Crystallization
The expression, purification and crystallization of APGM
were performed as described previously (Nogly et al., 2012).
Briefly, the pgmH gene coding for APGM in L. lactis
(Q00G41) was cloned into pNZ8048 vector with a His6 tag at
the N-terminus followed by an enterokinase cleavage site. The
APGM construct of 29.9 kDa was homologously expressed
in L. lactis and purified by metal-affinity (Ni–NTA) chroma-
tography. Crystals appeared in 2M ammonium sulfate, 0.1M
HEPES pH 7.5, 2% PEG 400 using the vapour-diffusion
method at room temperature. Subsequently, streak-seeding
from the initial multiple crystals was used to grow suitable
crystals for X-ray diffraction. Crystals were cryoprotected with
the crystallization solution supplemented with 20% glycerol
and flash-cooled in liquid nitrogen.
Native crystals were soaked in crystallization solutions
supplemented with heavy-atom compounds at room
temperature. The soaking times were 20 h for potassium
tetrachloroplatinate(II), potassium tetranitroplatinate(II),
trimethyllead acetate, thiomersal and potassium gold(III)
chloride, and one month for mercury(II) acetate and cisplatin.
The final concentrations of these compounds ranged from 2.5
to 15 mM.
2.2. Gel filtration
Size-exclusion chromatography was carried out to estimate
the molecular mass of APGM in solution using a Superdex 200
16/60 gel-filtration column equilibrated with 50 mM HEPES
pH 7.4, 150 mM NaCl. The calibration curve was prepared
using cytochrome c, carbonic anhydrase, albumin (BSA),
alcohol dehydrogenase and -amylase as standards.
2.3. Data collection and processing
X-ray diffraction data for APGM native crystals were
collected on the ID14-2 beamline of the European Synchro-
tron Radiation Facility (ESRF), Grenoble, France at 100 K.
The best crystal diffracted to 1.5 A˚ resolution and the data
were integrated using MOSFLM (Battye et al., 2011) and
scaled with SCALA (Evans, 2011; Nogly et al., 2012). A data
set from the crystal derivatized with K2PtCl4 was collected to
2.4 A˚ resolution on the I04 beamline of the Diamond Light
Source (DLS), Didcot, England at 100 K and the diffraction
data were integrated and scaled with XDS (Kabsch, 2010).
The other putative derivative data sets (data not shown) were
measured at the ESRF, the DLS or the SLS (Swiss Light
Source), Villigen, Switzerland and were processed with XDS.
2.4. Phasing and crystallographic refinement
The HKL2MAP graphical interface (Pape & Schneider,
2004) and SHELXD (Sheldrick, 2008) were used to search all
of the putative derivatives for heavy-atom sites. The only clear
solution was observed for the K2PtCl4 derivative, yielding 23
positive hits out of 100 trials, with the best solution showing
correlation coefficients CCall = 37.6% and CCweak = 21.6%. A
total of five probable Pt sites were found with occupancies
higher than 0.3 in space group P3121. However, SHELXE
(Sheldrick, 2008) did not produce an interpretable electron-
density map. Therefore, the initial set of five sites was input
into SHARP/autoSHARP (Bricogne et al., 2003; Vonrhein et
al., 2007) for further refinement and phasing, with a phasing
research papers
Acta Cryst. (2013). D69, 2008–2016 Nogly et al.  Atypical -phosphoglucomutase 2009
power (anomalous) of 1.622 and a figure of merit (acentric) of
0.343. After density modification with SOLOMON (Abra-
hams & Leslie, 1996), an interpretable electron-density map
was obtained at 2.4 A˚ resolution. Phase extension to include
the higher resolution native data set was not successful, very
likely owing to non-isomorphism between the Pt-derivative
and native crystals. Nevertheless, a partial backbone model of
the protein was built with Buccaneer (Cowtan, 2006). Based
on this incomplete model, it was possible to identify the non-
crystallographic symmetry (NCS)
between the two molecules in the
asymmetric unit. The NCS symmetry
operator was used for density modifi-
cation in DM (Cowtan, 1994), which
further improved the quality of the
calculated electron-density maps. Cycles
of automated model building with
Buccaneer and ARP/wARP (Langer et
al., 2008) alternating with manual model
building using Coot (Emsley et al., 2010)
yielded a crystallographic model that
was about 80% complete. Molecular
replacement was then carried out with
Phaser (McCoy et al., 2007) using this
partial model as a search template
against the higher resolution native data
set. The structure was completed and
refined to 1.5 A˚ resolution using Coot
and REFMAC5 (Murshudov et al.,
2011). In the final refinement cycles, the
model was refined using TLS groups as
generated with the TLSMD server
(Painter & Merritt, 2006) and with H
atoms added at ideal positions (Chen et
al., 2010) and used as riding atoms.
The coordinates and structure factors
have been deposited in the Protein Data
Bank with accession code 4bnd.
3. Results and discussion
3.1. Model quality and APGM structure
The APGM crystal soaked with
K2PtCl4 diffracted to 2.4 A˚ resolution
and belonged to space group P3121,
with unit-cell parameters a = b = 67.4,
c = 212.6 A˚. Two protein molecules are
present in the asymmetric unit, showing
a root-mean-square deviation (r.m.s.d.)
between C atoms of 0.35 A˚. The esti-
mated solvent content is around 46.5%.
The structure of APGM was solved by
single-wavelength anomalous disper-
sion (SAD) using the K2PtCl4 deriva-
tive. Relevant parameters for data
collection and processing of the deri-
vative data are shown in Table 1. The final APGM model was
refined to 1.5 A˚ resolution, with an R factor of 15.5% and an
Rfree of 17.8% (Bru¨nger, 1992). The crystallographic model
showed good geometry and stereochemistry (PROCHECK;
Laskowski et al., 1993). All amino-acid residues lie within the
allowed regions of the Ramachandran plot (RAMPAGE;
Lovell et al., 2003).
The electron-density maps are very well defined for the
protein backbone, except for the region comprising Ile9 and
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Table 1
X-ray data and structure-refinement statistics.
Values in parentheses are for the highest resolution shell.
Pt derivative Native†
Data collection
X-ray source Beamline I04, DLS Beamline ID14-1, ESRF‡
Wavelength (A˚) 0.9722 0.9334
Temperature (K) 100 100
Detector ADSC Quantum Q315r ADSC Quantum Q210‡
No. of images 250 1400
Rotation range per image () 0.4 0.1
Space group P3121 P3121
Unit-cell parameters (A˚) a = b = 67.4, c = 212.6 a = b = 67.17, c = 210.39
No. of molecules per asymmetric unit 2 2
Matthews coefficient VM (A˚
3 Da1) 2.34 2.30
Solvent content (%) 47.4 46.5
Resolution range (A˚) 50.00–2.40 (2.54–2.40) 33.00–1.50 (1.58–1.50)
Total No. of reflections 129424 (17888) 744514 (105892)
No. of unique reflections 41740 (6489) 89350 (12888)
Completeness (%) 98.5 (95.1) 100.0 (100.0)
Average multiplicity 3.1 (2.8) 8.3 (8.2)
Average I/(I) 25.76 (10.91) 16.8 (3.1)
Rmerge 0.028 (0.089) 0.084 (0.707)
Rp.i.m. 0.026 (0.056) 0.031 (0.260)
Overall B factor from Wilson plot (A˚2) 42.6 15.0‡
Anomalous correlation§ (%) 58
No. of Pt sites finally modelled 8
Refinement
PDB code 4bnd
Resolution range (A˚) 30.05–1.50
No. of reflections 89249
No. of reflections in test set for Rfree 4470
Rwork/Rfree 0.157/0.180
No. of atoms
Total 8806
Protein 8110
H atoms (riding) 4075
Ligand 94
Water 602
Average B factors (A˚2)
Overall 19.5
Protein 18.6
Glycerol 31.4
Sulfate 14.5
Water 30.3
R.m.s. B} (A˚2)
All bonded atoms 1.47
Bonded main-chain atoms 1.37
Bonded side-chain atoms 1.57
Atoms involved in nonbonded interactions 5.00
R.m.s. deviations
Bond lengths (A˚) 0.016
Bond angles () 1.759
Ramachandran favoured†† (%) 98.2
Ramachandran outliers†† (%) 0
† Detailed description in Nogly et al. (2012). ‡ The information reported in Table 1 of Nogly et al. (2012) is corrected
here. § Percentage of correlation between random half-sets of anomalous intensity differences computed in XDS
(Kabsch, 2010). } Calculated withMOLEMAN2 (Kleywegt, 1997). †† Statistics based on RAMPAGE (Lovell et al.,
2003).
Asp10 in molecule B. The side chains of
12 surface residues are not fully visible
in the final 2|Fo|  |Fc| electron-density
map contoured at 1, likely owing to
their mobility, and 26 side chains were
modelled with alternate conformations,
including the catalytic residue Asp8. A
blob of residual electron density was
observed near the active site of the
enzyme (cap domain). Based on its
tetrahedral shape and the nearby resi-
dues, a sulfate ion was fitted into the
blob and further refined. Six glycerol
molecules were added to the model, one
of which is close to the sulfate ion in
chain B. The final APGM model
comprises 404 amino-acid residues (252
per chain), 602 water molecules, two
sulfate ions and six glycerol molecules.
Each molecule comprises a core
domain (residues 1–88 and 189–252),
typical of the HADSF, and a small cap
domain (residues 93–183) as illustrated
in Fig. 1(a). The core domain consists of
a seven-stranded -sheet (5, 4, 3,
2, 1, 10 and 11) flanked by five -
helices (6, 7, 8, 1 and 2). The cap
domain is constituted by a four-stranded
antiparallel -sheet (6, 7, 9 and 8)
with three -helices located on one face
(3, 5 and 4). The cap and core
domains are connected by two linker
loops (89–92 and 184–188) that may act
as a hinge joint. Indeed, HingeProt (Emekli et al., 2008)
predicts a more mobile region around residues 88 and 188
(Fig. 1a).
The APGM active site is located at the interface between
the core and cap domains. This interface comprises several
positively charged residues, such as Lys17 and Lys44 in the
core domain and Arg128, Lys140 and Lys146 in the cap
domain, which are proposed to keep the enzyme in an open
conformation, a feature that is also observed in PMMs
(Silvaggi et al., 2006). In the structure of human PMM1 the
substrate is bound to the cap domain in the cap-open
conformation, which was suggested to represent the first
encounter complex (Silvaggi et al., 2006). Upon binding of the
negatively charged substrate (i.e. -glucose-1-phosphate) in
the cap domain, the electrostatic repulsion between the cap
and core domains may be shielded, favouring the closure of
the cap domain and the proper positioning of the substrate
with respect to catalytic residues in the core domain. A closed
cap domain also provides a solvent-excluded environment.
The core domain contains the conserved catalytic residues of
the HADSF (see below for further details), while the cap
domain has a more variable size and structure and thus is
proposed to be involved in substrate recognition. The
topology and location of the cap domain allows the classifi-
cation of APGM into the type IIb subfamily of the HADSF
(Allen & Dunaway-Mariano, 2004).
3.2. Similar structures
The overall structure of APGM is similar to eukaryotic
phosphomannomutases (PMMs), despite their low sequence
identity (up to 24%). The four best hits from DALI were (the
PDB entry, Z-score and r.m.s.d. for C superposition are
indicated for each hit): Leishmania mexicana PMM (2i55, 23.7,
2.9 A˚; Kedzierski et al., 2006), Trypanosoma brucei PMM
(3f9r, 24.2, 3.0 A˚; Structural Genomics Consortium, unpub-
lished work), human PMM1 (2fue, 20.1, 4.1 A˚; Silvaggi et al.,
2006) and human PMM2 (2amy, 17.4, 5.3 A˚; Center for
Eukaryotic Structural Genomics, unpublished work). Super-
position of APGM with these four crystal structures shows
that the cap domain is more tightly closed in APGM than in
PMMs (Fig. 1b). In contrast, the structure of human PMM2
(PDB entry 2amy) without any ligand bound at the domain
interface has the cap domain furthest away from the core
domain. The structure of leishmanial PMM (PDB entry 2i55)
may well illustrate the cap closure upon ligand binding as a
result of alleviated electrostatic repulsion between the
domains: polypeptide chain A has no ligand at the active site,
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Figure 1
Structure of APGM and comparison with PMMs. (a) APGM ribbon representation (molecule B)
coloured according to the secondary-structure elements assigned byDSSP (Kabsch & Sander, 1983)
and HingeProt (-strands, yellow; -helices, magenta; turns, pink; hinges, spheres). Glycerol and
sulfate located at the interface of the core and cap domains are drawn in stick mode. Atom colour
codes: C, green; O, red; S, yellow. Figs. 1 and 3 were drawn with CCP4mg (McNicholas et al., 2011).
(b) Structural superposition of APGM and PMMs, aligned by the core domains (with
SwissPDBViewer; Guex & Peitsch, 1997), showing the different conformations of the cap domain
relative to the core domain, with APGM being most closed (depicted in red; chain A). The PDB
code identifies the PMM structures: 2i55, L. mexicana PMM; 2fue, human PMM1, 2amy; human
PMM2; 3f9r, T. brucei PMM.
whereas chain B has a ligand bound and thus is in a more
closed conformation. The ligand, -glucose 1,6-bisphosphate,
extensively interacts with both domains. Remarkably, the
structure of human PMM1 bound to mannose 1-phosphate
(PDB entry 2fue) was captured in a cap-open state with the
substrate interacting mainly with residues from the cap
domain. This structure was obtained by soaking the ligand into
pre-formed crystals, which was proposed to restrict the
movements of the cap domain within the crystal lattice
(Silvaggi et al., 2006).
Binding of sulfate at the phosphoryl binding site (as in
APGM and PDB entry 3f9r), rather than larger ligands (as in
PDB entry 2i55 and 2fue), is likely to result in a more closed
conformation of the cap domain. However, the structure of
T. brucei PMM with sulfate displays a more open conforma-
tion than APGM. The positive patch at the interface of
T. brucei PMM comprises Arg19 and Lys50 in the core
domain, and Arg122, Arg133 and Arg140 in the cap domain
and is highly conserved among PMMs. However, in APGM
the Lys140 side chain is oriented towards the solvent, which
could mitigate the electrostatic repulsion between the posi-
tively charged residues at the APGM domain interface, thus
allowing a more tightly closed cap conformation.
APGM shows several insertion regions with regard to
PMMs (Fig. 2), which are mainly located at the molecular
surface of the core domain, namely between helix 2 and
strand 3, between strands 4 and 5, between helix 3 and
strand 6 (cap domain), and between helix 6 and strand 10.
These insertions are not expected to cause major structural
differences in APGM compared with PMMs, except for that at
the cap domain, as discussed below.
3.3. Quaternary structure
The molecular mass of APGM estimated by size-exclusion
chromatography was 55 kDa, indicating the presence of a
dimeric form in solution. The dimeric assembly proposed by
PISA (Krissinel & Henrick, 2007) corresponds to a crystal
contact in the APGM structure (Fig. 3a). The complexation
significance score (CSS) for the polypeptide suggests that
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Figure 2
Amino-acid sequence alignment based on structural superimposition of APGM with PMMs performed with the DALI server. Black arrows indicate
domain boundaries. Relevant amino-acid residues are displayed in bold with the following residue colour code: red, involved in substrate interaction;
blue overline, positive charged residues at the cap–core interface; green, residues forming the dimer interface. Below the sequence alignment, conserved
residues are indicated by an asterisk (*) and similar residues by a dot (.). Blue arrows represent -strands and red tubes represent -helices.
the interface plays an essential role in complex formation.
The occluded area at this interface is approximately 1000 A˚2
(around 5% of the total area) and is formed by hydrophobic
amino-acid residues mainly located in the C-terminal helix 8
and hydrophilic residues sited on the stretch between 11 and
8 (core domain). It also includes waters mediating hydrogen
bonds between the two molecules. This dimeric arrangement
should represent the biological unit of APGM and may be
relevant to the enzyme function, as it brings the active sites
within the dimer into proximity. It is worth noting that in
APGM helix 8 is shifted further away from the -sheet of the
same monomer towards 8 and 11 of the other monomer
than in PMMs and thus forms a hydrophobic groove accom-
modating residues sited on 8 of the other molecule within the
dimer.
The dimeric assembly proposed for L. mexicana PMM
shows a different interface formed exclusively by amino-acid
residues from the cap domains (Kedzierski et al., 2006). The
dimer formation includes a helix–helix interaction between
the first helices (3) and an antiparallel -sheet interaction
between the first strands (6) of the two cap domains, which
extends the solvent-exposed face of the -sheet, placing the
two active sites adjacent to each other. This interface is also
conserved in human PMMs (Silvaggi et al., 2006) and likely in
T. brucei PMM (as predicted by the PISA server). Structure-
based sequence alignment of APGM with these four homo-
logous PMMs shows a five-residue-insertion in this region of
the cap domain between helix 3 and strand 6 (Fig. 2).
Structural superposition reveals that the loop comprising
Leu110–Glu123 adopts a different conformation in APGM,
including a protrusion (Glu115–Glu123) facing outwards,
which may explain why APGM cannot form the same dimeric
assembly as the aforementioned PMM structures (Fig. 3b).
3.4. Active site and catalytic mechanism
APGM catalyzes the interconversion of -glucose 1-phos-
phate and glucose 6-phosphate via a phophorylated enzyme
intermediate, as proposed for other phosphoryl-transfer
enzymes of the HADSF (Dai et al., 2006; Kedzierski et al.,
2006). The enzyme first has to be activated by the transfer of a
phosphate from the -glucose 1,6-bisphosphate cofactor to the
enzyme aspartyl nucleophile (Asp8 in APGM), producing an
aspartyl phosphate (Supplementary Fig. S11). The substrate
(-glucose 1-phosphate) then binds, forming a covalent bond
between the substrate C6 hydroxyl O atom and the aspartyl-
phosphate P atom. An -glucose-1,6-bisphosphate intermediate
is generated, which then needs to be released from the enzyme
and rebound in a reoriented position so that the 1-phosphate
is transferred to the aspartyl nucleophile, replenishing the
activated form of the enzyme and forming the final product
(glucose 6-phosphate). Release of the phosphate from the
bisphospho-carbohydrate intermediate to the aspartyl group is
facilitated by another acid/base group (Asp10). The catalytic
nucleophile (Asp8) usually coordinates a magnesium ion
along with other residues and water molecules. No metal ion
is observed in the APGM crystal structure and no Mg2+ ions
were present in the crystallization buffer.
Although the relevance of the APGM dimer to its catalytic
activity has not yet been demonstrated, in this arrangement
the two active sites are placed face to face with the sulfate ions
38 A˚ apart. Interestingly, an extended positively charged
patch is observed in a groove between the active sites,
comprising two arginine residues (Arg234A/B) and two lysine
residues (Lys237A/B). The positive charge between the active
sites may prolong the presence of the intermediate within the
dimer instead of its release into the solution. A functional role
has also been proposed for the dimeric forms of human and
leishmanial phosphomannomutases (Kedzierski et al., 2006;
Silvaggi et al., 2006).
The unsuccessful attempts to obtain the structure of APGM
in complex with substrate analogues either by crystal soaking
or cocrystallization may be due to the presence of sulfate in
the APGM active site (Lu et al., 2005). Sulfate exchange for
malonate was also attempted, but resulted in crystal degra-
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Figure 3
Comparison of APGM and PMM dimers. (a) The APGM dimer identified
by PISA. Molecule B is coloured blue and molecule A is coloured green
(dark colour for the core domain and light colour for the cap domain).
Sulfate and glycerol are located at the substrate-binding site. (b) Dimer of
leishmanial PMM (grey) illustrating the conserved dimeric interface of
eukaryotic PMMs. Superimposition with one molecule of APGM (core,
dark blue; cap, cyan) by the cap domain, highlighting the longer loop in
APGM.
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: DZ5291). Services for accessing this material are described at the
back of the journal.
dation (McPherson, 2001). Nevertheless, important informa-
tion on substrate binding can be derived from the homologous
PMM structures, in particular those of human PMM1 in
complex with -mannose 1-phosphate and leishmanial PMM
in complex with -glucose 1,6-bisphosphate. In fact, the sulfate
bound at the active site of APGM molecules A and B overlays
quite well with the phosphoryl group (bound to C1) of
-glucose 1,6-bisphosphate bound to the L. mexicana PMM
structure (Fig. 4). Moreover, if the cap domains of the APGM
and human PMM1 structures are superposed, the sulfate ion
in APGM also matches the position of the phosphoryl group
of -mannose 1-phosphate. In the APGM structure, the
sulfate is hydrogen bonded to the main-chain amide and side-
chain hydroxyl groups of Thr177, Thr178 and Thr179, Lys146
and a few water molecules. It is also close to Gln43 from the
core domain (4.1 and 3.1 A˚ in molecules A and B, respec-
tively). In all four eukaryotic PMM structures from the DALI
survey, this distal sulfate/substrate phosphoryl-binding pocket
(cap domain) is mainly composed by two
arginines and one serine (Arg143, Arg150
and Ser188; human PMM1 numbering).
In addition, the glycerol found near the
sulfate ion (molecule B, closest distance of
4.1 A˚) aligns very well with part of the
pyranose ring of -glucose 1,6-biphosphate
bound to the leishmanial PMM structure. In
APGM, the two hydroxyl groups of glycerol
that mimic part of the sugar moiety establish
hydrogen bonds to the side chains of Arg128
and Asn181 (corresponding to Arg122 and
Asp180 in leishmanial PMM), the main-
chain amide-group peptide hydrogen of
Gly42 and a few water molecules. It is worth
noting that in the APGM structure the side
chain of Asp10 is hydrogen bonded to one
glycerol hydroxyl (corresponding to the C6 hydroxyl of the
PMM ligand) in molecule B, while in molecule A, in the
absence of glycerol, it is shifted 2.8 A˚ towards the interior of
the active-site pocket. In contrast, in PMMs the corresponding
Asp side chain is further away from the ligand (7 A˚ from the
C6 atom of glucose in leishmanial PMM), with the exception
of human PMM1, in which the acid/base Asp is in a confor-
mation corresponding to molecule B of APGM. The mobility
of Asp10, which plays an important role in the catalytic
mechanism, is clearly evident from the different positions
adopted by this acid/base residue in APGM and PMMs. Also,
the poorly defined electron density around the backbones of
Ile9 and Asp10 in molecule B suggests flexibility and possibly
alternate conformations. In addition, in the active site of
molecule B the side chain of Asp8 adopts alternate confor-
mations; two water molecules are observed to mediate
contacts between this aspartate and glycerol.
Moreover, we have fitted -glucose 1,6-bisphosphate into
APGM, based on the previous superposition with leishmanial
PMM, and a model with reasonable stereochemistry was
obtained except for Ser41, which lies too close (1.3 A˚) to the
phosphoryl group (Fig. 4). This residue is replaced by a
conserved glycine in PMMs. A shift of the molecule towards
Asp8 and a slight rotation around the phosphodiester bond
followed by geometry idealization with REFMAC5
(Murshudov et al., 2011) provided a good fit of the ligand into
the binding pocket (Fig. 5).
A relevant point to discuss is the strict specificity of APGM
towards -glucose 1-phosphate, in contrast to PMMs, which
can use both -glucose 1-phosphate and mannose 1-phosphate
as substrates. The only difference between these two sugars is
the position of the hydroxyl group at C2 of the pyranose ring
(equatorial in -glucose 1-phosphate and axial in mannose
1-phosphate). Structural superimposition of APGM with
leishmanial PMM shows that the side chain of Gln43 in
APGM lies in close proximity to C2 of the pyranose ring of
-glucose 1,6-bisphosphate (Gln43 N"2 is only 2.3 A˚ away
from C2). This residue restricts the space under the sugar ring,
which may be needed to accommodate the phosphomannose
(Fig. 5). If the hydroxyl group of C2 is in the axial position,
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Figure 5
Active site of APGM fitted with -glucose 1,6-bisphosphate (manual
fitting followed by structure idealization). van der Waals surfaces of the
Gln43 side chain and phosphosugar ligand are coloured green and pink,
respectively, highlighting the steric restrictions imposed by Gln43 below
the C2 atom of the sugar ring.
Figure 4
Stereoview of the APGM active site. Superposition of APGM and leishmanial PMM
structures, highlighting the alignment of glycerol and sulfate (APGM; C, green; alternate
conformation of Asp8) with -glucose 1,6-bisphosphate (leishmanial PMM; C, grey; P,
magenta).
as in mannose 1,6-bisphosphate, it would clash with the side
chain of Gln43. This steric hindrance in the presence of
phosphomannose may prevent the full closure of the cap over
the core domain and restrict the proper positioning of the
phosphomannose to react with the catalytic residues in the
core domain. This Gln43 is replaced by a strictly conserved
serine in PMMs and no steric hindrance is observed. This
amino-acid substitution is likely to be responsible for the strict
specificity of APGM towards -glucose 1-phosphate.
In addition, the crystal structure of human PMM1 with
mannose 1-phosphate was proposed to represent the first
encounter state of the ligand with the enzyme (Silvaggi et al.,
2006). The cap domain is found in an open conformation and
the residues engaged in the interactions with the ligand are
mainly from the cap domain. In this structure, the hydroxyl
group at C2 of the pyranose ring is hydrogen bonded to
Arg132, Asn137 and Asp190. The corresponding residues in
APGM are Arg128, Ala133 and Asn181. The substitution of
Asn by Ala affects the enzyme–substrate interactions, as no
hydrogen bond can be established by Ala in APGM. Because
the cap domain accounts for substrate recognition and
binding, the weaker interactions with mannose 1-phosphate in
APGMmay also contribute to its specificity towards -glucose
1-phosphate.
4. Conclusions
Here, we have presented the first high-resolution structure
of L. lactis -phosphoglucomutase (APGM) with substrate-
mimicking sulfate and glycerol bound at the active site. Unlike
other bacterial -phosphoglucomutases, APGM belongs to
the haloacid dehalogenase superfamily with structural
features showing the characteristic catalytic core and mobile
cap domains. The enzyme cap domain is found in a tightly
closed conformation. APGM is found to be a dimer in solution
as well as in the crystal structure, which might be relevant to
the enzyme efficiency; however, the dimer interface differs
from that found in eukaryotic PMMs. Despite low sequence
identity, APGM shares structural homology with eukaryotic
phosphomannomutases, although it can only utilize -glucose
1-phosphate and not its stereoisomer -mannose 1-phosphate,
unlike PMMs. Structural superposition of APGM and PMMs
highlights their similarity and differences. A relevant differ-
ence seems to be the replacement of the conserved Gly and
Ser residues in PMMs by Ser41 and Gln43, respectively, in
APGM, which adds steric constraints at the APGM active site.
The presented work provides the first structural insights into
this atypical -phosphoglucomutase.
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